Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer

Premiere Date: Friday, September 3, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Saturday, September 3, 2022
Note: Credit Is No Longer Available

Faculty

Cora N. Sternberg, MD, FACP (Moderator) Clinical Director, Englander Institute for Precision Medicine Professor of Medicine Sandra and Edward Meyer Cancer Center Weill Cornell Medicine New York, NY

William K. Oh, MD  Clinical Professor of Medicine Division of Hematology and Medical Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, NY Chief Medical Science Officer, Sema4 Stamford, CT

Statement of Need

Androgen deprivation therapy (ADT) is a standard first-line treatment of patients with metastatic castration-sensitive prostate cancer (CSPC). ADT is highly effective, convenient, durable, and associated with an acceptable quality of life, however, castration resistance inevitably develops. The utilization of second-generation antiandrogen therapies can delay progression, but the choice of therapeutic combinations requires individualization.

In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and the role of molecular testing risk stratification of patients with metastatic CSPC.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Select appropriate therapy for men with metastatic CSPC.
• Appraise molecular diagnostic approaches to risk stratify patients with metastatic CSPC.

Financial Support

Supported by an educational grant from Astellas and Pfizer, Inc.

Target Audience

Urologists, medical oncologists, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Sternberg reports that is a consultant for Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Foundation Medicine, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; National Cancer Institute; Pfizer Inc.; Genentech, Inc./Roche; Sanofi Genzyme; and UroToday.

Dr. Oh reports that he is a consultant for Advanced Accelerator Applications; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Conjupro Biotherapeutics, Inc.; Curio Biotech Ltd; Foundry; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc. ; Sanofi; and TeneoBio.

David Modrak, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).